Interferon (IFN) regulates immune responses and antitumor activity. Arginine-glycine-aspartic acid (RGD) peptides can specifically bind to integrin [alpha]v[beta]3, a transmembrane receptor that is highly expressed on the surface of various cancer cells. In this study, we expressed recombinant RGD-IFN-[alpha]2a-core fusion proteins and assessed their antitumor activity in vitro. Two RGD-IFN-[alpha]2a-core fusion proteins and a negative control protein were expressed in vitro. These two RGD-IFN-[alpha]2a-core fusion proteins could bind the tumor cell surface specifically and did not bind to normal cells. RGD-IFN-[alpha]2a-core fusion protein treatment of tumor cells significantly reduced cell viability and induced apoptosis in a dose-dependent manner. At the 'mRNA' level, both proteins could upregulate CASP3 expression. These data indicate that both laboratory-engineered RGD-IFN-[alpha]2a-core fusion proteins could bind the surface of tumor cells and induce apoptosis in vitro. Further studies will investigate the in-vivo antitumor activities of the RGD-IFN-[alpha]2a-core fusion proteins. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially. http://ift.tt/1hexVwJ Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved.
http://ift.tt/2enSpsr
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου